Check out the latest in sleep health! From the impact of dialysis on sleep to the benefits of catching up on sleep for heart health, August brought key insights into the importance of rest. Plus, new findings on sleep treatments and more. hcplive.com/view/sleep-mon… #SleepHealth

The European Commission has revoked the conditional marketing authorization of obeticholic acid (Ocaliva) in Europe for the second-line treatment of patients with #PBC, weeks ahead of an FDA advisory committee meeting for its sNDA in the US. Learn more: hcplive.com/view/european-…

New phase 3 data from plozasiran, a small interfering RNA therapy, presented at #ESCCongress indicates there could be hope on the horizon for patients with FCS. Learn more: hcplive.com/view/palisade-… #Lipids

Investigators noted that a formal independent validation cohort needs to be developed in order to realize the full potential of the human model. Read more: hcplive.com/view/machine-l… #ArtificialIntelligence

Need a refresher on all things #ophthalmology from August 2024? Check out our ophthalmology month in review, which recaps top regulatory and pipeline news as well as the latest clinically impactful data in the field. hcplive.com/view/ophthalmo…

Post-hoc analysis of #STEP trials shows #semaglutide for #weight management doesn't increase #depression or #suicide risk in patients without major psychiatric disorders. hcplive.com/view/semagluti…

Our August 2024 #hepatology month in review recaps some of our top coverage of the latest #hepatic news and research from the past few weeks. Check it out here: hcplive.com/view/hepatolog… #LiverTwitter

New real-world research has shown that patients with #IBD are satisfied with all adalimumab biosimilar and reference treatments. hcplive.com/view/patient-s… #Biosimilars

ICYMI: Yesterday, ARS Pharmaceuticals announced pre-ordering availability of their epinephrine nasal spray (neffy), which received a first-of-its-kind approval from the FDA in early August. hcplive.com/view/neffy-epi… #Allergy #FDANews

Did you miss anything featured in our #dermatology news coverage from August? Check out our 'Month in Review' article summarizing some of the most significant developments in the field of skin health. View here: hcplive.com/view/dermatolo…

ICYMI: The latest #DontMissABeat spotlighted the FINEARTS-HF trial and examined the potential of finerenone in HFpEF moving forward. #ESCCongress hcplive.com/view/dont-miss…

In an interview Thomas Wadden, PhD, Penn Medicine gave insights into recently published data which found #semaglutide does not increase #depession risk in people without a known mental health disorder. hcplive.com/view/thomas-a-…

Did you miss anything featured in our #dermatology news coverage from August? Check out our 'Month in Review' article summarizing some of the most significant developments in the field of skin health. View here: hcplive.com/view/dermatolo…

August was a busy month in #nephrology – check out our month in review for a recap of HCPLive’s coverage of the top #renal news and research from the past few weeks: hcplive.com/view/nephrolog…

Once-daily vadadustat was non-inferior to darbepoetin alfa for the treatment of #Anemia in patients with dialysis-dependent #ChronicKidneyDisease. Read more 👇 hcplive.com/view/daily-vad…

Meet Michael, a busy patient with type 2 #diabetes who is gaining weight—despite efforts to diet—and is worried about hypoglycemia. In this interactive #CE/CME, you’ll help him navigate and make decisions as his case progresses. Earn 1.5 free credits: bit.ly/3T0W57k

Check out the latest in rheumatology news, with updates in the last month on bimekizumab's efficacy in treating PsA and risk factors for developing #gout. #RheumTwitter Read more here: hcplive.com/view/rheumatol…

MTX + HCQ combination therapy has demonstrated greater efficacy in treating rheumatoid arthritis (RA) than MTX alone, with a statistically similar safety profile. #RheumTwitter hcplive.com/view/methotrex…